SG10201807588TA - Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers - Google Patents
Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancersInfo
- Publication number
- SG10201807588TA SG10201807588TA SG10201807588TA SG10201807588TA SG10201807588TA SG 10201807588T A SG10201807588T A SG 10201807588TA SG 10201807588T A SG10201807588T A SG 10201807588TA SG 10201807588T A SG10201807588T A SG 10201807588TA SG 10201807588T A SG10201807588T A SG 10201807588TA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- combination
- scaffolds
- present
- various cancers
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 230000001024 immunotherapeutic effect Effects 0.000 title abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. NO FIGURE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562211276P | 2015-08-28 | 2015-08-28 | |
GBGB1515321.6A GB201515321D0 (en) | 2015-08-28 | 2015-08-28 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201807588TA true SG10201807588TA (en) | 2018-10-30 |
Family
ID=54326487
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202001830PA SG10202001830PA (en) | 2015-08-28 | 2016-08-26 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
SG10202001831SA SG10202001831SA (en) | 2015-08-28 | 2016-08-26 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
SG10201807588TA SG10201807588TA (en) | 2015-08-28 | 2016-08-26 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202001830PA SG10202001830PA (en) | 2015-08-28 | 2016-08-26 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
SG10202001831SA SG10202001831SA (en) | 2015-08-28 | 2016-08-26 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
Country Status (18)
Country | Link |
---|---|
US (7) | US10525114B2 (en) |
EP (2) | EP3341014A1 (en) |
JP (2) | JP6970974B2 (en) |
KR (3) | KR102308798B1 (en) |
CN (1) | CN107921111B (en) |
AU (3) | AU2016313684B2 (en) |
BR (1) | BR112018003460A2 (en) |
CA (2) | CA3072922A1 (en) |
CR (6) | CR20200495A (en) |
EA (2) | EA201890560A1 (en) |
GB (1) | GB201515321D0 (en) |
MA (7) | MA43459A1 (en) |
MX (1) | MX2018002480A (en) |
PE (2) | PE20181517A1 (en) |
SG (3) | SG10202001830PA (en) |
TW (15) | TWI722664B (en) |
UA (1) | UA124577C2 (en) |
WO (1) | WO2017036936A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
RU2729116C2 (en) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Identification, production and use of neoantigens |
JP7075125B2 (en) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
CN108250286B (en) * | 2016-12-28 | 2021-06-08 | 香雪生命科学技术(广东)有限公司 | Tumor antigen short peptide derived from PASD1 |
US10899819B2 (en) | 2017-04-10 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
EP3609531A2 (en) | 2017-04-10 | 2020-02-19 | immatics biotechnologies GmbH | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
DE102017115966A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptide molecule with improved dual specificity |
EP3428194B1 (en) | 2017-07-14 | 2021-08-18 | Immatics Biotechnologies GmbH | Improved dual specificity polypeptide molecule |
AU2018338975A1 (en) * | 2017-09-28 | 2020-04-16 | Gavish-Galilee Bio Applications Ltd. | A universal platform for preparing an inhibitory chimeric antigen receptor (iCAR) |
KR20200087143A (en) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | Identification of new antigens using hot spots |
JP2021503897A (en) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | Reduced junction epitope presentation for nascent antigens |
DE102018107224A1 (en) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers |
TW202016131A (en) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | Peptides for use in immunotherapy against cancers |
CN109467596B (en) * | 2018-11-12 | 2021-11-09 | 湖北省农业科学院畜牧兽医研究所 | Application of transcription factor SP1 in regulation and control of pig RTL1 gene expression |
CN109738929B (en) * | 2018-12-03 | 2022-10-21 | 中国辐射防护研究院 | Dose estimation method and system based on maximum consumption of resident food |
TW202042836A (en) * | 2019-02-18 | 2020-12-01 | 日商肽夢想股份有限公司 | Hemagglutinin-binding peptide |
JPWO2020230792A1 (en) * | 2019-05-13 | 2020-11-19 | ||
CN110123453B (en) * | 2019-05-31 | 2021-07-23 | 东北大学 | Operation navigation system based on unmarked augmented reality |
CN111910000B (en) * | 2020-07-02 | 2022-07-01 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Tumor microenvironment component marker combination and system for predicting nasopharyngeal carcinoma prognosis |
EP4326306A1 (en) * | 2021-04-19 | 2024-02-28 | Board of Regents, The University of Texas System | Methods and compositions comprising mhc class i peptides |
CN115607573B (en) * | 2022-12-16 | 2023-05-23 | 北京大学第三医院(北京大学第三临床医学院) | Method for regulating activity of killer T cells, medicine and application thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776729A (en) * | 1995-06-05 | 1998-07-07 | Human Genome Sciences, Inc. | Human G-protein receptor HGBER32 |
JP2002507397A (en) * | 1998-03-13 | 2002-03-12 | エピミューン,インコーポレイティド | HLA binding peptides and uses thereof |
US7342108B2 (en) * | 1998-06-25 | 2008-03-11 | The General Hospital Corporation | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof |
JP4315301B2 (en) | 1998-10-30 | 2009-08-19 | 独立行政法人科学技術振興機構 | Human H37 protein and cDNA encoding this protein |
US6680197B2 (en) * | 1998-12-28 | 2004-01-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
CA2311201A1 (en) * | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
US20040002068A1 (en) * | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
GB0119473D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
US6953672B2 (en) * | 2001-08-21 | 2005-10-11 | Millennium Pharmaceuticals, Inc. | Screen for CDC7 inhibitors |
US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
DE10316701A1 (en) | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | New nucleic acid, and derived proteins, useful for diagnosis of bronchial cancer and in screening for therapeutic and diagnostic agents |
EP1622934A2 (en) * | 2003-05-05 | 2006-02-08 | Pharmacia Italia S.p.A. | Truncated forms of human dbf4, complexes with their interacting partners and methods for identification of inhibitors thereof |
EP1522594A3 (en) | 2003-10-06 | 2005-06-22 | Bayer HealthCare AG | Methods and kits for investigating cancer |
JP4721903B2 (en) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | Novel tumor antigen protein and use thereof |
WO2009008414A1 (en) * | 2007-07-10 | 2009-01-15 | Shionogi & Co., Ltd. | Monoclonal antibody having neutralizing activity against mmp13 |
SI2183361T1 (en) * | 2007-07-27 | 2015-09-30 | Immatics Biotechnologies Gmbh | Novel immunotherapy against brain tumors |
EP2565204B1 (en) | 2007-07-27 | 2015-10-07 | immatics biotechnologies GmbH | Novel immunogenic epitopes for immunotherapy |
EP2220245B1 (en) * | 2007-10-17 | 2015-04-22 | The Board of Trustees of The Leland Stanford Junior University | Method and composition for crystallizing g protein-coupled receptors |
WO2009123568A1 (en) | 2008-03-31 | 2009-10-08 | Agency For Science, Technology & Research | High efficiency linear transmitter |
TW201000115A (en) * | 2008-06-11 | 2010-01-01 | Oncotherapy Science Inc | IQGAP3 epitope peptides and vaccines containing the same |
WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
SI2172211T1 (en) | 2008-10-01 | 2015-03-31 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
ITBO20090075A1 (en) * | 2009-02-13 | 2010-08-14 | Magneti Marelli Spa | ELECTRIC MACHINE WITH SINGLE STATOR AND TWO ROTORS BETWEEN THEM INDEPENDENT AND ROAD VEHICLE PROVIDED WITH THIS ELECTRIC MACHINE |
GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
WO2012048291A2 (en) * | 2010-10-08 | 2012-04-12 | Proteapex Therapeutics Llc | Compositions and methods for inhibition of mmp:mmp-substrate interactions |
EP2670440B1 (en) * | 2011-02-01 | 2018-09-05 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
JP2014526682A (en) | 2011-09-12 | 2014-10-06 | クリエイティクス エルエルシー | Non-invasive method for detecting target molecules |
WO2013070603A1 (en) | 2011-11-11 | 2013-05-16 | Cedars-Sinai Medical Center | Compositions and methods for treatment of kidney diseases |
EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9878056B2 (en) * | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
CA2880331A1 (en) | 2012-08-15 | 2014-02-20 | Universite De Montreal | Method for identifying novel minor histocompatibility antigens |
EP3636665B1 (en) * | 2012-09-14 | 2022-06-29 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing mhc class ii-restricted mage-a3 |
US9134326B2 (en) | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
TWI777198B (en) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same |
WO2015092710A1 (en) * | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
TW202016131A (en) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | Peptides for use in immunotherapy against cancers |
US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
-
2015
- 2015-08-28 GB GBGB1515321.6A patent/GB201515321D0/en not_active Ceased
-
2016
- 2016-08-26 TW TW108141499A patent/TWI722664B/en active
- 2016-08-26 TW TW108141489A patent/TWI722655B/en active
- 2016-08-26 MA MA43459A patent/MA43459A1/en unknown
- 2016-08-26 CR CR20200495A patent/CR20200495A/en unknown
- 2016-08-26 MA MA43457A patent/MA43457A1/en unknown
- 2016-08-26 SG SG10202001830PA patent/SG10202001830PA/en unknown
- 2016-08-26 MA MA43460A patent/MA43460A1/en unknown
- 2016-08-26 UA UAA201808797A patent/UA124577C2/en unknown
- 2016-08-26 TW TW108141491A patent/TWI722657B/en active
- 2016-08-26 EA EA201890560A patent/EA201890560A1/en unknown
- 2016-08-26 BR BR112018003460-6A patent/BR112018003460A2/en active Search and Examination
- 2016-08-26 TW TW108141492A patent/TWI722658B/en active
- 2016-08-26 KR KR1020187023153A patent/KR102308798B1/en active IP Right Grant
- 2016-08-26 PE PE2018001375A patent/PE20181517A1/en unknown
- 2016-08-26 TW TW107128393A patent/TWI699377B/en active
- 2016-08-26 TW TW105127400A patent/TW201708246A/en unknown
- 2016-08-26 MA MA042694A patent/MA42694A/en unknown
- 2016-08-26 SG SG10202001831SA patent/SG10202001831SA/en unknown
- 2016-08-26 TW TW108141495A patent/TWI722660B/en active
- 2016-08-26 KR KR1020217031080A patent/KR102515909B1/en active IP Right Grant
- 2016-08-26 MA MA43458A patent/MA43458A1/en unknown
- 2016-08-26 KR KR1020187007555A patent/KR20180038550A/en not_active Application Discontinuation
- 2016-08-26 CR CR20180423A patent/CR20180423A/en unknown
- 2016-08-26 CR CR20200494A patent/CR20200494A/en unknown
- 2016-08-26 EA EA201891874A patent/EA201891874A3/en unknown
- 2016-08-26 PE PE2018000318A patent/PE20181164A1/en unknown
- 2016-08-26 TW TW108141497A patent/TWI722662B/en active
- 2016-08-26 TW TW108141490A patent/TWI722656B/en active
- 2016-08-26 SG SG10201807588TA patent/SG10201807588TA/en unknown
- 2016-08-26 WO PCT/EP2016/070146 patent/WO2017036936A1/en active Application Filing
- 2016-08-26 CA CA3072922A patent/CA3072922A1/en active Pending
- 2016-08-26 TW TW108141487A patent/TWI722653B/en active
- 2016-08-26 CR CR20180174A patent/CR20180174A/en unknown
- 2016-08-26 MX MX2018002480A patent/MX2018002480A/en unknown
- 2016-08-26 TW TW108141488A patent/TWI722654B/en active
- 2016-08-26 CR CR20200493A patent/CR20200493A/en unknown
- 2016-08-26 TW TW108141496A patent/TWI722661B/en active
- 2016-08-26 CA CA2996963A patent/CA2996963A1/en active Pending
- 2016-08-26 MA MA43461A patent/MA43461B1/en unknown
- 2016-08-26 JP JP2018511114A patent/JP6970974B2/en active Active
- 2016-08-26 CR CR20200492A patent/CR20200492A/en unknown
- 2016-08-26 EP EP16762752.0A patent/EP3341014A1/en active Pending
- 2016-08-26 EP EP18201208.8A patent/EP3461494A1/en active Pending
- 2016-08-26 MA MA045073A patent/MA45073A/en unknown
- 2016-08-26 TW TW109122012A patent/TWI782290B/en active
- 2016-08-26 AU AU2016313684A patent/AU2016313684B2/en active Active
- 2016-08-26 TW TW108141494A patent/TWI722659B/en active
- 2016-08-26 CN CN201680050119.7A patent/CN107921111B/en active Active
- 2016-08-26 TW TW108141498A patent/TWI722663B/en active
-
2018
- 2018-05-17 US US15/982,500 patent/US10525114B2/en active Active
- 2018-05-17 US US15/982,293 patent/US10576132B2/en active Active
- 2018-10-18 AU AU2018250464A patent/AU2018250464B2/en active Active
-
2019
- 2019-11-04 US US16/673,619 patent/US10695411B2/en active Active
- 2019-11-04 US US16/673,608 patent/US10568950B1/en active Active
-
2020
- 2020-03-16 AU AU2020201896A patent/AU2020201896B2/en active Active
- 2020-05-29 US US16/887,765 patent/US10898557B2/en active Active
- 2020-06-29 US US16/915,420 patent/US10898558B2/en active Active
- 2020-09-10 US US17/017,358 patent/US11065316B2/en active Active
-
2021
- 2021-04-23 JP JP2021072989A patent/JP7506026B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018250464B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
PH12018500551A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
PH12018500848A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
PH12018500864A1 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
MX2018005273A (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers. | |
SG10201806839PA (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
MX2017011857A (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers. | |
PH12017502279A1 (en) | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | |
PH12018500004A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | |
MX2018011388A (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers. | |
MX2021001622A (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors. | |
MY196837A (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
MX2022005570A (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers. |